Beijing's Annoroad Collaborates with Illumina on Prenatal Diagnostic
June 12, 2015 at 04:32 AM EDT
Annoroad Gene Technology, headquartered in Beijing's E-Town Biomedical Park, will work together with Illumina to develop a next-gen non-invasive prenatal DNA diagnostic test for the China market. Annoroad will contribute its expertise with nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide next generation sequencing instruments and related reagents. Their goal is to create a highly accurate, easy-to-use system. More details.... Stock Symbol: (NSDQ: ILMN) Share this with colleagues: // //